Taipei Exchange - Delayed Quote TWD

GlycoNex Incorporation (4168.TWO)

Compare
24.00
0.00
(0.00%)
At close: 1:30:31 PM GMT+8

Key Executives

Amounts are as of -- and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in TWD.
NameTitlePayExercisedYear Born
Dr. Mei-Chun Yang President, CEO & Manager -- -- --
Ti-Fen Wu Chief Financial Officer & Accounting Supervisor -- -- --
Yaohua Lu Vice President of Administration -- -- --

GlycoNex Incorporation

No. 97, Xintai 5th Road
8th Floor Sec. 1 Xizhi District
New Taipei City, 221
Taiwan
886 2 2697 4168 https://www.glyconex.com.tw
Sector: 
Healthcare
Industry: 
Biotechnology

Description

GlycoNex Incorporation engages in the development of cancer drugs using glycosphingolipid antigen and human monoclonal antibody technologies in Taiwan. The company's development pipeline for the treatment of solid tumors includes GNX102, a humanized monoclonal antibody, currently under phase 1 clinical stage; GNX201, an antibody drug currently under lead optimization stage; GNX202, an antibody drug currently under preclinical stage; and GNX203 and GNX204, antibody drugs currently under target validation stage. It is also involved in the development of SPD (Denosumab), a humanized IgG2 antibody that is in preclinical stage for the treatment of osteoporosis and oncology; and SEA (Aflibercept), a vascular endothelial growth factor binding fusion protein, currently under lead optimization stage for the treatment of ophthalmology and oncology. The company was incorporated in 2001 and is based in New Taipei City, Taiwan.

Corporate Governance

GlycoNex Incorporation’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

Recent Events

August 5, 2013 at 12:00 AM UTC

Ex-Dividend Date

Related Tickers

4167.TWO Savior Lifetec Corporation
19.75
-0.25%
 
3176.TWO Medigen Biotechnology Corp.
32.60
-1.21%
 
3205.TWO Sagittarius Life Science Corp
33.95
-1.59%
 
6461.TWO Intech Biopharm Corporation
24.85
+0.20%
 
4157.TWO TaiGen Biopharmaceuticals Holdings Limited
10.70
0.00%
 
4726.TWO Mycenax Biotech Inc.
40.25
0.00%
 
6492.TWO Senhwa Biosciences, Inc.
42.35
+0.47%
 
4174.TWO OBI Pharma, Inc.
56.90
+1.25%
 
4192.TWO SynCore Biotechnology Co.,Ltd
33.40
-0.15%
 
4131.TWO NeoCore Technology Co., Ltd.
31.00
0.00%